An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Both drugs were given as a subcutaneous injection every eight weeks after ... more failed anti-tumour necrosis factor (TNF) therapies. Stelara was first launched in 2009 and has been J&J's top ...

When first starting Stelara, it is given as a single IV dose, followed by a subcutaneous injection every eight weeks. Xeljanz ...

Several headwinds are impacting the company, including generic competition for its blockbuster drug Stelara, the ongoing talc lawsuit (which could see a final decision in the first half of the ...

Investors are watching biosimilar competition with immunology drug Stelara, which extended to the key US market in January. We assume a more than $3 billion decline in global Stelara sales in 2025.

Overall, global Stelara sales dropped 14.7% year-over-year to roughly $2.3 billion in 2024’s fourth quarter. For the full 12-month earnings period, Stelara sales slipped around 4.6% to $10.4 ...